A nationwide medication recall has been issued for a specific batch of thyroid medication distributed across the United States. Vitruvias Therapeutics Inc. voluntarily initiated a recall for one lot of its Thyroid Tablets, USP 30 mg, after product testing confirmed that the tablets might be superpotent.
The U.S. Food and Drug Administration (FDA) published the company’s voluntary recall notice, warning that taking tablets with higher-than-intended levels of active thyroid hormones can lead to hyperthyroidism and serious secondary health complications.
If you or a loved one relies on daily thyroid hormone replacement therapy, here is a complete, easy-to-understand breakdown of the recall details, health risks, vulnerable populations, and immediate steps you should take.
1. Quick Recall Summary: Key Details at a Glance
To determine whether your medication is affected, check the outer packaging or bottle label for the National Drug Code (NDC), lot number, and expiration date.
| Product Parameter | Details |
| Product Name | Thyroid Tablets, USP 30 mg |
| Recalling Firm | Vitruvias Therapeutics Inc. (Auburn, AL) |
| National Drug Code (NDC) | 69680-166-00 |
| Affected Lot Number | 504950 |
| Expiration Date | September 30, 2026 (9/30/2026) |
| Distribution Period | January 31, 2025 – September 30, 2025 |
| Total Units Released | 3,655 |
| Total Units Sold | 1,955 |
The affected lot was shipped directly to wholesale accounts and distributors nationwide throughout 2025.
2. Why Was the Medication Recalled?
The primary reason for this recall is superpotency. During routine quality testing, samples from Lot 504950 showed active ingredient levels that exceeded required pharmaceutical specifications.
┌───────────────────────────────────────────────────────────┐
│ UNDERSTANDING POTENCY │
├─────────────────────────────┬─────────────────────────────┤
│ Standard Dose (30 mg) │ Superpotent Batch (Lot 504950)
│ • Expected hormone level │ • Higher active hormone level │
│ • Controls hypothyroidism │ • Triggers hyperthyroidism │
└─────────────────────────────┴─────────────────────────────┘
Thyroid, USP is a natural desiccated thyroid (NDT) preparation derived from porcine (pig) thyroid glands. It contains two primary thyroid hormones:
- Levothyroxine ($T_4$)
- Liothyronine ($T_3$)
When a thyroid tablet is superpotent, it delivers a larger dose of $T_3$ and $T_4$ than your doctor prescribed. Consuming too much thyroid hormone pushes the body’s metabolic engine into overdrive, turning an underactive thyroid treatment into an induced state of overactive thyroid (hyperthyroidism).
3. Recognizing Symptoms of Hyperthyroidism
Taking a superpotent dose of thyroid hormone alters your metabolic rate, cardiovascular performance, and central nervous system. Symptoms can range from mild discomfort to severe medical emergencies depending on how long you have taken the medication.
[ Superpotent Thyroid Supplement Intake ]
│
▼
[ Excess T3 & T4 in Bloodstream ]
│
┌───────────────┴───────────────┐
▼ ▼
[ Cardiovascular Overdrive ] [ Metabolic & Nervous System ]
• Rapid Heart Rate (Tachycardia) • Unintended Weight Loss
• High Blood Pressure • Nervousness & Anxiety
• Chest Pain & Arrhythmias • Heat Intolerance & Fatigue
Common warning signs of excess thyroid hormone levels include:
Metabolic & Nervous System Warning Signs
- Unintended Weight Loss: Burning calories faster than usual despite normal or increased appetite.
- Heat Intolerance: Feeling abnormally warm or experiencing excessive sweating.
- Nervousness & Anxiety: Irritability, restiveness, mood swings, or hand tremors.
- Fatigue & Muscle Weakness: Feeling exhausted even after adequate rest due to elevated muscular strain.
Cardiovascular Warning Signs
- Tachycardia: A unusually rapid or racing heart rate.
- Palpitations: A sensation of fluttering or pounding in the chest.
- Hypertension: Elevated blood pressure readings.
- Chest Pain: Discomfort or tightness in the chest region.
To date, Vitruvias Therapeutics has reported no adverse event reports connected to this recall. However, signs of toxicity can build up slowly over time.
4. High-Risk Patient Groups
While excess thyroid hormone is problematic for anyone, three specific groups face elevated risks of severe or life-threatening complications.
┌─────────────────────────────┐
│ HIGH-RISK POPULATIONS │
└──────────────┬──────────────┘
│
┌───────────────────────┼───────────────────────┐
▼ ▼ ▼
[ Elderly Patients ] [ Pregnant Individuals ] [ Infants ]
• Severe Cardiac Events • Premature Delivery • Impaired Growth
• Arrhythmias & Strokes • Low Birth Weight • Developmental Delays
Elderly Patients
Older adults are particularly sensitive to fluctuations in $T_3$ and $T_4$ levels. Excess thyroid hormones increase the heart’s workload, which can trigger:
- Atrial Fibrillation: An irregular, rapid heart rhythm that increases the risk of stroke.
- Myocardial Ischemia: Reduced blood flow to the heart muscle, potentially leading to heart attacks or chest pain (angina).
- Bone Density Loss: Prolonged exposure to elevated thyroid levels accelerates bone mineral density loss, increasing fracture risks.
Pregnant Individuals
Maintaining precise thyroid hormone levels is crucial during pregnancy for both maternal health and fetal development. Overtreatment of hypothyroidism in pregnant individuals can lead to:
- Higher incidence of premature labor and delivery.
- Increased risk of low birth weight.
- Preeclampsia or maternal high blood pressure spikes.
Infants and Children
For infants receiving thyroid hormone replacement, excessive dosing can interfere with central nervous system development and skeletal growth:
- Accelerated Bone Age: Premature closure of growth plates, affecting adult height.
- Growth and Developmental Delays: Disruption of natural pediatric developmental milestones.
5. Critical Guidance: Do NOT Stop Taking Your Medication Abruptly
If you discover that your pill bottle is from Lot 504950, your immediate instinct might be to toss the bottle in the trash and stop taking your medication right away. Health officials and physicians explicitly advise against doing this.
[ FOUND RECALLED LOT #504950 ]
│
▼
[ DO NOT STOP MEDICATION ABRUPTLY ]
│
▼
[ Contact Prescribing Doctor / Pharmacist ]
│
┌────────────────────┴────────────────────┐
▼ ▼
[ Obtain Replacement Prescription ] [ Safely Dispose Recalled Lot ]
Why Abrupt Discontinuation Is Dangerous
Stopping thyroid replacement therapy cold turkey causes a sharp drop in blood hormone levels. This can trigger a rebound effect, plunging your body from potential hyperthyroidism back into severe hypothyroidism. Symptoms of sudden hypothyroidism include extreme fatigue, severe brain fog, cold intolerance, depression, rapid weight gain, and muscle pain.
Recommended Step-by-Step Action Plan
- Locate Your Pill Bottle: Examine the label for NDC 69680-166-00 and Lot 504950.
- Call Your Doctor or Pharmacist Immediately: Explain that your current prescription bottle is part of the Vitruvias Lot 504950 recall.
- Request an Alternative or Replacement: Your pharmacist can provide a replacement supply from a safe, non-recalled batch or contact your physician to switch to a suitable alternative medication.
- Continue Taking Your Current Dose Until Guided Otherwise: Unless your physician instructs you to stop immediately, continue taking your daily medication while waiting for your replacement prescription to arrive.
6. How Manufacturers Manage Recalls & Wholesaler Guidance
When a pharmaceutical manufacturer initiates a voluntary recall at the consumer level, a coordinated response begins across the pharmaceutical supply chain:
- Direct Account Notification: Vitruvias Therapeutics is actively contacting wholesalers, distributors, and direct accounts via phone and email.
- Quarantine and Destruction: Wholesalers are instructed to immediately quarantine remaining inventory of Lot 504950 and arrange for its destruction.
- FDA Oversight: The recall is monitored by the FDA to verify that the manufacturer removes all affected inventory from retail and hospital pharmacies.
7. Contact Information & Reporting Adverse Events
If you have questions about the recall process or need to report side effects, use the following official contact channels:
Contact Vitruvias Therapeutics Inc.
- Phone: (256) 239-9373(Available Monday through Friday, 9:00 a.m. to 5:00 p.m. Central Time)
- Email: safety@vitruvias.com
Reporting Side Effects to the FDA MedWatch Program
If you have experienced health issues related to this recalled medication, you can submit a report directly to the FDA’s MedWatch Adverse Event Reporting program:
- Online Reporting: Submit a report directly at the.
- Phone: Call 1-800-332-1088 to request a reporting form.
- Fax or Mail: Complete the downloadable form and submit it by fax to 1-800-FDA-0178 or mail it using the pre-addressed form.
Frequently Asked Questions
How do I find the lot number on my prescription bottle?
The lot number is printed directly on the prescription label or on the side of the original manufacturer’s bottle. It is usually printed near the expiration date and preceded by “Lot,” “Batch,” or “L.” If your pharmacy replaced the original bottle with a generic orange prescription vial, the lot number may still be printed on the sticker label. If you cannot find it, call your dispensing pharmacy.
Are other doses or lots of Vitruvias Thyroid Tablets recalled?
No. This recall applies only to Thyroid Tablets, USP 30 mg, specifically Lot 504950 (NDC 69680-166-00). Other strengths (such as 15 mg, 60 mg, or 90 mg) and other lot numbers are not affected by this recall notice.
What is the difference between synthetic thyroid medication and natural desiccated thyroid?
Synthetic thyroid medications (like levothyroxine) contain only synthetic $T_4$ hormone, whereas natural desiccated thyroid (NDT) products (like Thyroid, USP) are derived from animal thyroid glands and contain both $T_4$ and $T_3$ hormones.